Arrhythmias & electrophysiology
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation
Main finding · Composite of cardioversion, new AAD therapy or repeat AF ablation after 3-month blanking periodResult — go to the resultHazard ratio 1.04 95% CI 0.92–1.19Authors' conclusion
These findings suggest that preprocedural use of GLP-1 RAs is not associated with a reduced risk of AF recurrence or associated adverse outcomes following ablation
Study context
- Population
- Patients aged ≥18 years undergoing atrial fibrillation (AF) ablation, TriNetX database, 2014–2023matched cohort
- Participants
- 1,625 vs 1,625
- Exposure
- Preablation GLP-1 RA use vs nonuse
- GLP-1 RA usersn = 1,625
- Nonusersn = 1,625reference
- Outcome
- Composite of:
- Cardioversion
- New antiarrhythmic drug therapy
- Repeat AF ablation after a 3-month blanking period
Methodological detailspropensity-score matched (1:1)
- Propensity-score matched (1:1)
Main finding
As reported in the abstract
Composite of:
- Cardioversion
- New AAD therapy
- Repeat AF ablation after 3-month blanking period
Hazard ratio
1.04
95% CI 0.92–1.19
log-rank P = 0.51
Preablation GLP-1 RA usevs nonuse
HR 1.04 (95% CI 0.92–1.19); log-rank P = 0.51
Observational data: associations, not effects.
Further findings
Ischemic stroke, all-cause hospitalization, mortality · 12 months
- Did not differ between the 2 groups
Original publication
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation. JACC Clin Electrophysiol. Published 22 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →